Breast cancer version 2.2015.
Breast cancer version 2.2015. J Natl Compr Canc Netw. 2015 Apr;13(4):448-75 Authors: Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R Abstract Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. The overall management of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and the treatment of systemic disease with cytotoxic chemotherapy, endocrine therapy, biologic therapy, or combinations of these. This portion of the NCCN Guidelines discusses recommendations specific to the locoregional management of clinical stage I, II, and IIIA (T3N1M0) tumors. PMID: 25870381 [PubMed - in process]
1. The breast is the most heavily guarded and protected part of a woman ’s body. This means there is good reason to worry less. Did you know that a mammogram is one of only two imaging tests (the other being a low-dose lung cancer screening for former or current heavy smokers) paid for by insurance companies in the U.S. for asymptomatic patients without any risk facto rs? It is the only part of a woman’s body which gets scrutinized every year. Finding breast cancer early (stage 1: less than…
In conclusion, the attenuation of AE2 and its supportive enzyme CA12, and the inhibitory effect on cell migration by Disulfiram treatment in cancer cells provided the molecular evidence supporting the potential of Disulfiram as an anticancer agent.
Conclusions: Associations between metformin use and pancreatic cancer incidence or colorectal cancer OS are supported by strong or highly suggestive evidence, respectively. However, these results should be interpreted with caution due to the poor methodological quality of the systematic reviews and meta-analyses.
ConclusionsAlcohol consumption was minimally associated with all-cancer risk. Cigarette smoking clearly increased all-cancer risk, with females being more affected than males. Combined use of alcohol and tobacco increased the risk of developing all, colon, and prostate cancers. A “U-shaped” multiplicative interaction was observed for breast cancer when alcohol and tobacco were used in combination.
ConclusionsThe combination of belinostat 2000 mg/m2 days 1 –5 and 13-cRA 100 mg/m2 days 1 –14, every 21 days, was well-tolerated and an MTD was not reached despite doubling the established single-agent MTD of belinostat.
Cancer survival rates for esophagus, stomach, colon, rectum, pancreas, lung,...Read more on AuntMinnie.comRelated Reading: AI predicts lung cancer survival from CT scan data Lancet: Cancer survival rates improve but vary widely Cancer deaths continue to fall, but CT lung screening lags ACS: U.S. cancer death rates continue to fall NEJM: Treatment, not screening, cuts breast cancer deaths
In this study we showed that treatment with ouabain (25 nM) caused simultaneous activation of AMPK and Src signaling pathways in human lung cancer A549 cells and human breast cancer MCF7 cells. Cotreatment with AMPK inhibitor compound C or siRNA greatly abrogates ouabain-induced Src activation, whereas cotreatment with Src inhibitor PP2 has little effect on ouabain-induced AMPK activity, suggesting that AMPK served as an upstream regulator of the Src signaling pathway. On the other hand, ouabain treatment greatly depletes ATP production in A549 and MCF7 cells, and supplement of ATP (100 μM) blocked ouabain...
Lung cancer is the leading cause of cancer mortality among men and second to breast cancer among women. Up to 85 –90% of cases are attributed to cigarette smoking. Around 85% of patients are diagnosed with non-small cell lung carcinoma (NSCLC), with approximately 80% diagnosed at stages III and IV. Median survival of patients treated with numerous combination chemotherapies has been around 1 year, with ver y few patients surviving more than 3 years after diagnosis. Targeted therapies have changed the prognosis for a select group of patients who harbor a tumor-specific oncogene that could be targeted.
Brivanib is a selective inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discontinuation trial of brivanib in 7 tumour types (soft-tissue sarcomas [STS], ovarian cancer, breast cancer, pancreatic cancer, non-small-cell lung cancer [NSCLC], gastric/esophageal cancer and transitional cell carcinoma [TCC]).
Publication date: Available online 10 September 2019Source: Genes &DiseasesAuthor(s): Swati Sucharita Mohanty, Prafulla Kumar MohantyBreast cancer is the second highest prevalent cancer globally after lung cancer with 2.09 million cases during 2018. Adults about 1.9 billion were overweight and over 650 million out of these were obese during 2016. There is a significant relationship between breast cancer risk and obesity. Premature menopause and premenopausal obesity diminish the risk whereas postmenopausal obesity amplifies the risk, because adipose tissue acts as the major reservoir for estrogen biosynthesis after men...